Diabetes And Hypertension- Antihypertensive Medication Non-Use

Published Feb 17, 2014
Baltimore, MD, USA - High blood pressure affects about 70-80 percent of those with type 2 diabetes. To prevent complications associated with hypertension, such as heart attack, chronic kidney disease or blindness, in adults with diabetes, medical guidelines suggest tight blood pressure control, with prescription medications as a key treatment. Researchers at the University of Maryland Schools of Nursing and Medicine, and University of South Carolina College of Pharmacy compared the differences in health services utilization and medical costs between those using medications to control blood pressure versus non-users [in adults with diabetes and a diagnosis of hypertension]. They found that 16 percent of the estimated 38.7 million non-institutionalized U.S. adults with diabetes and coexistent essential hypertension did not use blood pressure controlling (antihypertensive) medications during a two-year span. Antihypertensive medication non-users had lower numbers of diabetes and hypertension related office visits, but greater numbers of all-cause hospitalizations than antihypertensive medication users. Antihypertensive medication non-users had greater odds of all-cause hospitalization, yet showed 29 percent lower average annualized and 27 percent lower total medical expenses. Dr. Davis-Ajami, PhD, MBA, MS, NP-C, Assistant Professor at the University of Maryland School of Nursing in Baltimore and lead author on the study, points out, “Medications play an important role in controlling blood pressure. We found significant numbers of adults not using antihypertensive medications among those adults one would expect to be taking such medications. Not surprisingly, there were greater hospitalizations among those not using antihypertensive medications in the presence of known hypertension and diabetes. During the two-year survey period, this did not result in higher medical costs. This cost finding differs from previous research and may reflect the lower number of office-based visits and lower prescription medication costs.  It may also show a potentially serious underlying disconnect from the health care system that over a life-time, may add up.” The full study, “Differences in Health Services Utilization and Costs between Antihypertensive Medication Users Versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009,” is published inValue in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×